Kyverna Therapeutics Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

112

Market Cap

275.04M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	7.03M	1.37M	24.20%
Dec 31, 2021	5.66M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

KYTX News

1 day ago - Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - GlobeNewsWire
6 days ago - Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
10 days ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 - GlobeNewsWire
13 days ago - Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - GlobeNewsWire
5 weeks ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - GlobeNewsWire
7 weeks ago - Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
2 months ago - Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event - GlobeNewsWire
2 months ago - Kyverna Therapeutics to Present at Upcoming Investor Conferences in September - GlobeNewsWire

More News